Fortress Biotech (FBIO) Stock Price

Fortress Biotech Price

NASDAQ·CLOSED
2.67USD-0.10 (-3.68 %)
Market closed

Over the last 10 years Fortress Biotech grew revenue by 53.6% annually, reaching 63.26 M USD. For Fortress Biotech, the net margin of 10.8% is up versus -94.1% a few years ago. The consensus 12-month price target for Fortress Biotech is 10.97 USD, about 310.7% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. Fortress Biotech's share price has gained 39.1% over the last twelve months. The stock trades about 39% above its 52-week low.

Fortress Biotech stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Fortress Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fortress Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fortress Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Fortress Biotech Stock Price History
DateFortress Biotech Price
8/7/20262.67 USD
8/6/20262.77 USD
8/5/20262.86 USD
8/4/20262.71 USD
8/3/20262.76 USD
7/31/20263.13 USD
7/30/20263.29 USD
7/29/20263.41 USD
7/27/20263.26 USD
7/23/20263.43 USD
7/22/20263.55 USD
7/21/20263.53 USD
7/20/20263.33 USD
7/17/20263.36 USD
7/16/20263.42 USD
7/15/20263.71 USD
7/14/20263.73 USD
7/13/20263.38 USD
7/10/20263.30 USD
7/9/20263.29 USD
7/8/20262.96 USD
7/7/20262.99 USD
7/6/20263.02 USD
7/2/20263.04 USD
7/1/20263.09 USD
6/30/20263.06 USD
6/29/20262.95 USD
6/26/20262.76 USD
6/25/20263.02 USD
6/24/20263.14 USD
6/23/20263.16 USD
6/22/20263.09 USD
6/18/20262.99 USD
6/17/20263.07 USD
6/16/20262.93 USD
6/15/20262.86 USD
6/12/20262.77 USD
6/11/20262.76 USD
6/10/20262.77 USD
6/9/20262.93 USD
6/8/20262.85 USD
6/5/20262.65 USD
6/4/20262.77 USD
6/3/20262.61 USD
6/2/20262.65 USD
6/1/20262.57 USD
5/29/20262.80 USD
5/28/20262.81 USD
5/27/20262.76 USD
5/26/20262.69 USD
5/22/20262.74 USD
5/21/20262.78 USD
5/20/20262.65 USD
5/19/20262.53 USD
5/18/20262.48 USD
5/15/20262.41 USD
5/14/20262.30 USD
5/13/20262.23 USD
5/12/20262.26 USD
5/11/20262.24 USD
5/8/20262.39 USD
5/7/20262.40 USD
5/6/20262.55 USD
5/5/20262.46 USD
5/4/20262.38 USD
5/1/20262.33 USD
4/30/20262.30 USD
4/29/20262.22 USD
4/28/20262.24 USD
4/27/20262.27 USD
4/24/20262.33 USD
4/23/20262.24 USD
4/22/20262.25 USD
4/21/20262.23 USD
4/20/20262.32 USD
4/17/20262.36 USD
4/16/20262.35 USD
4/15/20262.43 USD
4/14/20262.42 USD
4/13/20262.42 USD
4/10/20262.35 USD
4/9/20262.40 USD
4/8/20262.31 USD
4/7/20262.35 USD
4/6/20262.51 USD
4/2/20262.60 USD
4/1/20262.47 USD
3/31/20262.79 USD
3/30/20262.70 USD
3/27/20262.76 USD
3/26/20262.88 USD
3/25/20262.99 USD
3/24/20262.92 USD
3/23/20262.98 USD
3/20/20262.99 USD
3/19/20263.14 USD
3/18/20263.16 USD
3/17/20263.12 USD
3/16/20263.09 USD
3/13/20263.10 USD
3/12/20263.28 USD
3/11/20263.22 USD
3/10/20263.36 USD
3/9/20263.37 USD
3/6/20263.34 USD
3/5/20263.13 USD
3/4/20263.10 USD
3/3/20263.06 USD
3/2/20263.30 USD
2/27/20263.42 USD
2/26/20263.52 USD
2/25/20263.55 USD
2/24/20263.54 USD
2/23/20263.45 USD
2/20/20263.36 USD
2/19/20263.48 USD
2/18/20263.45 USD
2/17/20263.50 USD
2/13/20263.61 USD
2/12/20263.49 USD
2/11/20263.67 USD
2/10/20263.75 USD
2/9/20263.66 USD
2/6/20263.27 USD
2/5/20262.93 USD
2/4/20263.08 USD
2/3/20263.09 USD
2/2/20263.15 USD
1/30/20263.10 USD
1/29/20263.36 USD
1/28/20263.38 USD
1/27/20263.46 USD
1/26/20263.40 USD
1/23/20263.40 USD
1/22/20263.48 USD
1/21/20263.46 USD
1/20/20263.48 USD
1/16/20263.72 USD
1/15/20263.48 USD
1/14/20263.28 USD
1/13/20263.90 USD
1/12/20264.20 USD
1/9/20264.30 USD
1/8/20264.38 USD
1/7/20264.27 USD
1/6/20264.21 USD
1/5/20264.27 USD
1/2/20264.03 USD
12/31/20253.66 USD
12/30/20253.58 USD
12/29/20253.58 USD
12/26/20253.74 USD
12/24/20253.67 USD
12/23/20253.60 USD
12/22/20253.62 USD
12/19/20253.54 USD
12/18/20253.32 USD
12/17/20253.43 USD
12/16/20253.51 USD
12/15/20253.32 USD
12/12/20252.93 USD
12/11/20252.94 USD
12/10/20252.94 USD
12/9/20252.84 USD
12/8/20252.89 USD
12/5/20252.83 USD
12/4/20252.75 USD
12/3/20252.69 USD
12/2/20252.57 USD
12/1/20252.72 USD
11/28/20252.82 USD
11/26/20252.76 USD
11/25/20252.69 USD
11/24/20252.55 USD
11/21/20252.59 USD
11/20/20252.53 USD
11/19/20252.60 USD
11/18/20252.67 USD
11/17/20252.61 USD
11/14/20252.62 USD
11/13/20252.49 USD
11/12/20252.62 USD
11/11/20252.68 USD
11/10/20252.59 USD
11/7/20252.61 USD
11/6/20252.52 USD
11/5/20252.48 USD
11/4/20252.47 USD
11/3/20252.44 USD
10/31/20252.56 USD
10/30/20252.57 USD
10/29/20252.52 USD
10/28/20252.56 USD
10/27/20252.57 USD
10/24/20252.51 USD
10/23/20252.52 USD
10/22/20252.54 USD
10/21/20252.77 USD
10/20/20252.76 USD
10/17/20252.70 USD
10/16/20252.74 USD
10/15/20252.82 USD
10/14/20252.73 USD
10/13/20252.80 USD
10/10/20252.71 USD
10/9/20252.80 USD
10/8/20252.91 USD
10/7/20253.05 USD
10/6/20253.11 USD
10/3/20252.75 USD
10/2/20252.80 USD
10/1/20252.56 USD
9/30/20253.70 USD
9/29/20253.90 USD
9/26/20253.91 USD
9/25/20253.75 USD
9/24/20253.69 USD
9/23/20253.65 USD
9/22/20254.00 USD
9/19/20253.67 USD
9/18/20253.56 USD
9/17/20253.44 USD
9/16/20253.43 USD
9/15/20253.55 USD
9/12/20253.89 USD
9/11/20253.83 USD
9/10/20253.86 USD
9/9/20253.59 USD
9/8/20253.60 USD
9/5/20253.71 USD
9/4/20252.84 USD
9/3/20252.95 USD
9/2/20252.98 USD
8/29/20252.58 USD
8/28/20252.42 USD
8/27/20252.34 USD
8/26/20252.35 USD
8/25/20252.29 USD
8/22/20252.27 USD
8/21/20252.24 USD
8/20/20252.05 USD
8/19/20252.19 USD
8/18/20252.25 USD
8/15/20252.12 USD
8/14/20251.96 USD
8/13/20251.93 USD
8/12/20252.01 USD
8/11/20251.92 USD
Access this data via the Eulerpool API
Get Free API Key

Fortress Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
45.60 M USD
-94.27 M USD
-46.53 M USD
Jan 1, 2021
68.79 M USD
-188.54 M USD
-64.70 M USD
Jan 1, 2022
75.74 M USD
-203.05 M USD
-86.58 M USD
Jan 1, 2023
84.51 M USD
-141.72 M USD
-60.64 M USD
Jan 1, 2024
57.68 M USD
-109.70 M USD
-46.00 M USD
Jan 1, 2025
63.26 M USD
-70.22 M USD
6.82 M USD
Jan 1, 2026 (e)
79.88 M USD
-70.17 M USD
74.50 M USD
Jan 1, 2027 (e)
123.00 M USD
-108.05 M USD
-15.52 M USD

Fortress Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 2:40 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
––––16.00187.0026.0036.0045.0068.0075.0084.0057.0063.0079.00123.00
–––––1,068.75-86.1038.4625.0051.1110.2912.00-32.1410.5325.4055.70
––––31.2513.9076.9272.2268.8952.9458.6772.6263.1666.6766.6766.67
42.0042.0042.0042.005.0026.0020.0026.0031.0036.0044.0061.0036.0042.0052.6782.00
-27.00-35.00-20.00-50.00-67.00-93.00-121.00-110.00-94.00-188.00-203.00-141.00-109.00-70.00-70.00-108.00
––––-418.75-49.73-465.38-305.56-208.89-276.47-270.67-167.86-191.23-111.11-88.61-87.80
-27.00-37.00-20.00-48.00-55.00-66.00-84.00-39.00-46.00-64.00-86.00-60.00-45.006.0074.00-15.00
-25.0037.04-45.95140.0014.5820.0027.27-53.5717.9539.1334.38-30.23-25.00-113.331,133.33-120.27
1.632.382.492.632.682.752.873.985.325.586.047.8020.24279.02279.02279.02
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Fortress Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fortress Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fortress Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Fortress Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fortress Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Fortress Biotech stock margins

The Fortress Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fortress Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fortress Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
67.99 %
-206.74 %
-102.03 %
Jan 1, 2021
53.36 %
-274.08 %
-94.06 %
Jan 1, 2022
59.37 %
-268.07 %
-114.30 %
Jan 1, 2023
72.91 %
-167.69 %
-71.75 %
Jan 1, 2024
63.80 %
-190.20 %
-79.75 %
Jan 1, 2025
66.92 %
-111.00 %
10.77 %
Jan 1, 2026 (e)
66.92 %
-87.85 %
93.26 %
Jan 1, 2027 (e)
66.92 %
-87.85 %
-12.62 %

Fortress Biotech Stock Revenue, EBIT, Earnings per Share

The Fortress Biotech earnings per share therefore indicates how much revenue Fortress Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
8.57 USD
-17.72 USD
-8.74 USD
Jan 1, 2021
12.34 USD
-33.82 USD
-11.60 USD
Jan 1, 2022
12.54 USD
-33.61 USD
-14.33 USD
Jan 1, 2023
10.83 USD
-18.16 USD
-7.77 USD
Jan 1, 2024
2.85 USD
-5.42 USD
-2.27 USD
Jan 1, 2025
0.23 USD
-0.25 USD
0.02 USD
Jan 1, 2026 (e)
2.57 USD
-0.25 USD
2.40 USD
Jan 1, 2027 (e)
3.96 USD
-0.39 USD
-0.50 USD

Fortress Biotech business model & stock analysis

Fortress Biotech Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Fortress Biotech Employees
Details
Date
Fortress Biotech Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Fortress Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Fortress Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Fortress Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Fortress Biotech shares outstanding

The number of shares of Fortress Biotech was 279.02 M in 2025. This indicates how many shares Fortress Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
5.32 M Stocks
Jan 1, 2021
5.58 M Stocks
Jan 1, 2022
6.04 M Stocks
Jan 1, 2023
7.80 M Stocks
Jan 1, 2024
20.24 M Stocks
Jan 1, 2025
279.02 M Stocks
Jan 1, 2026 (e)
279.02 M Stocks
Jan 1, 2027 (e)
279.02 M Stocks

Fortress Biotech stock splits

In Fortress Biotech's history, there have been no stock splits.

Current Fortress Biotech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
10.97
Last Price
2.75
Currency
USD
12M Return Potential
298.73 %
LTM Return
0 %

Fortress Biotech Analyst Rating Actions

DateFirmActionRatingReliability
2/23/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/21/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/11/2025
Roth MKM
Roth MKM
MaintainedBuy–
11/18/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/19/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/16/2024
Roth MKM
Roth MKM
MaintainedBuy–
11/29/2023
Roth MKM
Roth MKM
MaintainedBuy–
8/15/2023
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
8/14/2023
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
5/16/2023
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Fortress Biotech Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/12/2026-0.20USD-18.67 MUSD-2026 Q2
5/13/2026-0.22USD-16.66 MUSD-2026 Q1
3/24/20260.11USD-26.69 MUSD-2025 Q4
11/14/2025-0.43USD-21.44 MUSD-2025 Q3
8/11/2025-0.37USD-14.82 MUSD-2025 Q2
11/12/2024-0.61USD-32.86 MUSD-2024 Q3
5/13/2024-3.06USD-21.93 MUSD-2024 Q1
3/28/2024-2.51USD-16.27 MUSD-2023 Q4
11/13/2023-0.08USD-43.15 MUSD-2023 Q3
8/9/2023-0.24USD-25.60 MUSD-2023 Q2

EESG©

Eulerpool ESG Scorecard© for the Fortress Biotech stock

33/100
38
Environment
13
Social
47
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fortress Biotech shareholder structure

% Name
3.27269%
Summit Financial, LLC
Summit Financial, LLC
2.74782%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.06958%
Kestra Advisory Services, LLC
Kestra Advisory Services, LLC
1.04871%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
1.03725%
PVG Asset Management Corporation
PVG Asset Management Corporation
0.89713%
Shikiar Asset Management, Inc.
Shikiar Asset Management, Inc.

Fortress Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
69.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
23.30%
Fortress Biotech, Inc. 20-5157386
Fortress Biotech, Inc. 20-5157386
SEC ↗
20.70%
Lindsay A. Rosenwald, M.D.
Lindsay A. Rosenwald, M.D.
SEC ↗
13.40%
Fortress Biotech, Inc.
Fortress Biotech, Inc.
SEC ↗
12.38%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
11.00%
1
1
SEC ↗
9.60%
Wilmot B. Harkey
Wilmot B. Harkey
SEC ↗
9.60%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
SEC ↗
9.60%
Daniel Mack
Daniel Mack
SEC ↗
7.85%
Hillel A. Gross
Hillel A. Gross
SEC ↗
7.80%
Highbridge Capital Management, LLC
Highbridge Capital Management, LLC
SEC ↗

Fortress Biotech Executives and Management Board

10 members · avg. age 63 · 20 % women

DJ

Mr. David Jin (35)

Chief Financial Officer and Head of Corporate Development

2.33 M USD

Management

LR

Dr. Lindsay Rosenwald (70)

Executive Chairman of the Board, President, Chief Executive Officer · since 2009

1.38 M USD
MW

Mr. Michael Weiss (59)

Executive Vice Chairman - Strategic Development, Director · since 2013

1.23 M USD
LL

Dr. Lucy Lu (50)

Chief Strategy Officer · since 2012

40,032.00 USD
JJ

Ms. Jaclyn Jaffe

Investor Relations · since 2017

–

Board of Directors

DK

Mr. Dov Klein (73)

Independent Director

120,065.00 USD
JL

Mr. J. Jay Lobell (62)

Independent Director

87,565.00 USD
JH

Dr. Jimmie Harvey (73)

Independent Director

67,565.00 USD
MH

Mr. Malcolm Hoenlein (81)

Independent Director

45,032.00 USD
KL

Mr. Kevin Lorenz (60)

Independent Director

40,032.00 USD

Frequently asked questions about Fortress Biotech

Analysts currently set an average price target of 10.97 USD for the Fortress Biotech stock (median: 10.97 USD), implying +298.7 % versus the latest price. The consensus is based on 8 analyst ratings.

Fortress Biotech Analyst Price Targets 2026

8 analysts currently rate the Fortress Biotech stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Fortress Biotech to generate revenue of 79.88 M USD and earnings per share of 0.27 USD.

Fortress Biotech Analyst Price Targets 2026

Converted at the current exchange rate, the Fortress Biotech share trades at 2.31 EUR (2.67 USD).

The Fortress Biotech share (FBIO) is listed on 4 stock exchanges, including: NASDAQ (FBIO), Frankfurt (CNB.F), München (CNB.MU), Düsseldorf (CNB.DU).

No history available for Fortress Biotech.

The expected revenue of Fortress Biotech is 79.88 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fortress Biotech is 74.50 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fortress Biotech is currently 10.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fortress Biotech stock.

The price-to-sales ratio (P/S) of Fortress Biotech is currently 9.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fortress Biotech stock.

The Eulerpool Quality Score for Fortress Biotech is 3/10.

The ISIN of Fortress Biotech is US34960Q3074. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Fortress Biotech is A14SJV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Fortress Biotech is FBIO. The ticker symbol is used to trade Fortress Biotech shares on the stock exchange.

Fortress Biotech paid dividends every year for the past 0 years.

Fortress Biotech is assigned to the 'Health' sector.

The dividends of Fortress Biotech are distributed in USD.

All fundamentals and in-depth analysis of Fortress Biotech

Our stock analysis for Fortress Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fortress Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Fortress Biotech Stock
Fortress Biotech Revenue→
Fortress Biotech Stock
Fortress Biotech Net Income→
Fortress Biotech Stock
Fortress Biotech P/E→
Fortress Biotech Stock
Fortress Biotech P/S→
Fortress Biotech Stock
Fortress Biotech EBIT→
Fortress Biotech Stock
Fortress Biotech Dividend→
Fortress Biotech Stock
Fortress Biotech Directors Dealings→
Fortress Biotech Stock
Fortress Biotech Stocks→
Fortress Biotech Stock
Fortress Biotech Market capitalization→
Fortress Biotech Stock
Fortress Biotech Debt→
Fortress Biotech Stock
Fortress Biotech Liabilities→
Fortress Biotech Stock
Fortress Biotech Equity→
Fortress Biotech Stock
Fortress Biotech AAQS→
Fortress Biotech Stock
Fortress Biotech Employees→
Fortress Biotech Stock
Fortress Biotech ROE→
Fortress Biotech Stock
Fortress Biotech ROA→
Fortress Biotech Stock
Fortress Biotech ROCE→
Fortress Biotech Stock
Fortress Biotech News→
Fortress Biotech Stock
Fortress Biotech Analyst Price Targets→

Health Stocks

Forza InnovationsFortrea HoldingsFrance Bed Holdings CoFortis Malar HospitalsFredun PharmaceuticalsFortis HealthcareFreliiForte BiosciencesFresenius Medical CareFormyconFresenius Medical CareFormosa PharmaceuticalsAll Stocks A–Z →